By name: 'liquid-biopsy-analytics-agent' description: 'Comprehensive analysis of liquid biopsy data (ctDNA, CTCs) for cancer detection, MRD monitoring, and response tracking.' keywords: - liquid-biopsy - ctdna - mrd - cancer-detection - treatment-response measurable_outcome: 'Detects circulating tumor DNA with 0.01% sensitivity and accurately predicts treatment response in longitudinal samples.' allowed-tools: - read_file - run_shell_command
Liquid Biopsy Analytics Agent
The Liquid Biopsy Analytics Agent provides comprehensive AI-driven analysis of blood-based cancer biomarkers. It integrates circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and cell-free RNA for multi-cancer early detection (MCED), minimal residual disease (MRD) monitoring, and treatment response assessment.
When to Use This Skill
- For multi-cancer early detection screening from blood samples.
- To monitor minimal residual disease (MRD) after curative treatment.
- When tracking tumor evolution and resistance during therapy.
- For real-time treatment response assessment.
- To detect cancer recurrence before clinical or imaging evidence.
Core Capabilities
ctDNA Mutation Analysis: Variant calling, VAF tracking, and clonal evolution from cell-free DNA.
Methylation-Based Detection: cfDNA methylation patterns for cancer detection and tissue-of-origin identification.
CTC Enumeration & Analysis: AI-powered CTC detection, enumeration, and molecular characterization.
Multi-Modal Integration: Combines ctDNA, CTCs, and protein biomarkers with clinical/imaging data.
MRD Monitoring: Ultra-sensitive detection of residual disease post-treatment.
Response Prediction: AI models predicting treatment response from longitudinal liquid biopsy data.
Analyte Types and Applications
| Analyte | Detection Method | Clinical Use |
|---|---|---|
| ctDNA mutations | NGS, ddPCR | Therapy selection, resistance |
| ctDNA methylation | WGBS, targeted | MCED, tissue of origin |
| ctDNA fragmentation | WGS | Cancer detection |
| CTCs | CellSearch, microfluidics | Prognosis, monitoring |
| Exosomes | Immunocapture | Biomarker cargo |
| cfRNA | RT-qPCR, NGS | Gene expression |
Workflow
Input: Liquid biopsy data (ctDNA variants, methylation, CTC counts, protein markers).
Quality Control: Assess sample quality, input DNA amount, background noise.
Variant Analysis: Call mutations, calculate VAF, filter artifacts (CHIP).
Multi-analyte Integration: Combine biomarker signals using ML fusion.
Clinical Interpretation: Generate actionable insights for treatment decisions.
Longitudinal Tracking: Model dynamics for response assessment and recurrence detection.
Output: Cancer detection probability, MRD status, treatment recommendations, clonal evolution.
Example Usage
User: "Analyze longitudinal ctDNA data from this lung cancer patient to assess treatment response and detect resistance."
Agent Action:
python3 Skills/Oncology/Liquid_Biopsy_Analytics_Agent/lb_analyzer.py \
--ctdna_variants longitudinal_ctdna.vcf \
--timepoints week0,week4,week8,week12 \
--tumor_markers cea_values.csv \
--baseline_tissue baseline_tumor.maf \
--analysis response_resistance \
--chip_filter true \
--output lb_report/
AI/ML Models
Multi-Cancer Early Detection (MCED):
- Methylation-based classifiers (sensitivity ~50-80% at 99% specificity)
- Multi-analyte combination models
- Tissue-of-origin prediction
- Integration with imaging and clinical risk
MRD Detection:
- Tumor-informed (personalized panels from tissue)
- Tumor-agnostic (fixed panels, methylation)
- Detection limits: 0.01% - 0.001% VAF
Response Prediction:
- Longitudinal VAF dynamics modeling
- Bayesian evolution frameworks
- Time-to-progression prediction
Clonal Hematopoiesis Filtering
Critical challenge in liquid biopsy interpretation:
| Gene | Prevalence | Action |
|---|---|---|
| DNMT3A | 30-40% of CHIP | Filter if VAF stable, no tumor context |
| TET2 | 20-30% | Filter if VAF stable |
| ASXL1 | 10-15% | Filter if VAF stable |
| TP53 | 5-10% | Context-dependent (tumor vs CHIP) |
| Matched WBC | Gold standard | Subtract germline/CHIP variants |
Commercial Platforms (Reference)
| Platform | Technology | Application |
|---|---|---|
| Guardant360 | ctDNA NGS | Therapy selection |
| FoundationOne Liquid | ctDNA NGS | Comprehensive profiling |
| Galleri | Methylation | MCED screening |
| Signatera | Tumor-informed | MRD monitoring |
| CellSearch | CTC | FDA-cleared enumeration |
Clinical Decision Points
- Treatment Selection: Actionable mutations (EGFR, ALK, ROS1, BRAF)
- Response Assessment: ctDNA clearance correlates with outcomes
- Resistance Detection: Emerging resistance mutations (T790M, C797S)
- Recurrence Monitoring: Lead time of 3-6 months over imaging
Prerequisites
- Python 3.10+
- NGS variant calling pipelines
- Methylation analysis tools
- Machine learning frameworks
Related Skills
- ctDNA_Analysis - For detailed ctDNA workflows
- Tumor_Clonal_Evolution - For evolutionary analysis
- MRD_Detection - For residual disease focus
Limitations and Considerations
- False positives: CHIP, benign tumors, inflammation
- False negatives: Low shedding tumors, early stage
- Technical variability: Pre-analytical factors critical
- Cost: Multi-analyte panels expensive
Author
AI Group - Biomedical AI Platform